* Topline results of Phase 3 investigational study of
Vonvendi [von Willebrand factor (recombinant)] meets primary
endpoint effectively controlling bleeding and blood loss during
surgical procedures
The post BRIEF-Shire says topline results of Phase 3 investigational study of Vonvendi meets primary endpoint appeared first on NASDAQ.